Skip to main content
SpringerLink
Log in

Device Management in Heart Failure

  • Heart Failure (HJ Eisen, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Medical devices have become an integral part of comprehensive heart failure management. Not all heart failure patients, however, accrue benefit from every new device, and even with extensive practice guidelines, this remains an evolving field.

Recent Findings

The addition of implantable devices, like internal cardioverter defibrillators (ICDs), and novel pacing technologies, including cardiac resynchronization therapy (CRT), have helped to compliment goal-directed medical therapy and positively impact prognosis in multiple high-quality clinical trials. This review attempts to summarize the rapidly evolving literature with respect to existing device guidelines for routine implantable devices as well as some available and future technologies that are not yet a part of routine guidelines.

Summary

ICD, CRT, and other implantable devices continue to save lives, decrease hospitalizations, and evolve the management of patients with heart failure beyond the capabilities of optimal guideline-directed medical therapy alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of Particular Interest, Published Recently, Have Been Highlighted as:• Of Importance•• of Major Importance

  1. Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2004;110:2180–3.

    Article  CAS  PubMed  Google Scholar 

  2. Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail. 1999;1:41–5.

    Article  CAS  PubMed  Google Scholar 

  3. Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-digoxin study group. J Am Coll Cardiol. 1989;14:564–70.

    Article  CAS  PubMed  Google Scholar 

  4. Szabó BM, van Veldhuisen DJ, Crijns HJ, et al. Value of ambulatory electrocardiographic monitoring to identify increased risk of sudden death in patients with left ventricular dysfunction and heart failure. Eur Heart J. 1994;15:928–33.

    Article  PubMed  Google Scholar 

  5. Doval HC, Nul DR, Grancelli HO, et al. Non sustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA- GEMA investigators. Circulation. 1996;94:3198–203.

    Article  CAS  PubMed  Google Scholar 

  6. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.

    Article  Google Scholar 

  7. Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91:2195–203.

    Article  CAS  PubMed  Google Scholar 

  8. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the cardiac arrest study Hamburg). Am Heart J. 1994;127(4 Pt 2):1139–44.

    Article  CAS  PubMed  Google Scholar 

  9. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.

    Article  CAS  PubMed  Google Scholar 

  10. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the cardiac arrest study Hamburg (CASH). Circulation. 2000;102:748–54.

    Article  CAS  PubMed  Google Scholar 

  11. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study Hamburg. Canadian implantable defibrillator study. Eur Heart J. 2000;21:2071–8.

    Article  CAS  PubMed  Google Scholar 

  12. • Bardy GH, Lee KL, Mark DB, et al. Sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. This trial justifies defibrillator therapy benefits in preventing sudden cardiac death.

    Article  CAS  PubMed  Google Scholar 

  13. Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Moss AJ, Zareba W, Hall WJ, et al. Multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.

    Article  PubMed  Google Scholar 

  15. • Goldenberg I, Moss AJ, McNitt S, et al. MADIT-II investigators. Time dependence of defibrillator benefit after coronary revascularisation in the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol. 2006;47:1811–7. This trial instructs the guidelines on ICD implantation following myocardial infarction and revascularization therapy.

    Article  PubMed  Google Scholar 

  16. Kadish A, Dyer A, Daubert JP. Et al; defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–8.

    Article  CAS  PubMed  Google Scholar 

  17. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874–9.

    Article  CAS  PubMed  Google Scholar 

  18. Priori SG, Blomström-Lundqvist C, Mazzanti A, Authors/Task Force Members; Document Reviewers, et al. 2015 ESC guidelines for the Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867.

    Article  PubMed  Google Scholar 

  19. Epstein AE, Kay GN, Plumb VJ, ACT Investigators, et al. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm. 2009;6:1136–43.

    Article  PubMed  Google Scholar 

  20. Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J. 2007;28:1746–9.

    Article  PubMed  Google Scholar 

  21. Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med. 2010;153:592–9.

    Article  PubMed  Google Scholar 

  22. Setoguchi S, Nohria A, Rassen JA, Stevenson LW, Schneeweiss S. maximum Potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure. CMAJ. 2009;180:611–6.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Dewland TA, Pellegrini CN, Wang Y, et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol. 2011;58:1007–13.

    Article  PubMed  Google Scholar 

  24. Gold MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator post-market approval study: clinical characteristics and perioperative results. Heart Rhythm. 2017; https://doi.org/10.1016/j.hrthm.2017.05.016.

  25. Young JB, Abraham WT, Smith AL, Multicenter InSync ICD Randomized Clinical Evaluation MIRACLE ICD) Trial Investigators, et al. Combined cardiac resynchronisation and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. 2003;289:2685–94.

    Article  PubMed  Google Scholar 

  26. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.

    Article  CAS  PubMed  Google Scholar 

  27. Cleland JG, Daubert JC, Erdmann E, Cardiac ResynchronizationHeart Failure (CARE-HF) Study Investigators, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.

    Article  CAS  PubMed  Google Scholar 

  28. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation. 2010;122:2022–30.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gold MR, Thébault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. Circulation. 2012;126:822–9.

    Article  PubMed  Google Scholar 

  30. Cunnington C, Kwok CS, Satchithananda DK, et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart. 2015;101:1456–62.

    Article  CAS  PubMed  Google Scholar 

  31. Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J. 2012;163:260–7.e3.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Moss AJ, Hall WJ, Cannom DS, MADIT-CRT Trial Investigators, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.

    Article  PubMed  Google Scholar 

  33. Tang AS, Wells GA, Talajic M, Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.

    Article  CAS  PubMed  Google Scholar 

  34. Wilkoff BL, Cook JR, Epstein AE, Dual Chamber and VVI Implantable Defibrillator Trial Investigators, et al. Dual-chamber pacing or ventricular back-up pacing in patients with an implantable defibrillator: the dual chamber and VVI implantable defibrillator (DAVID) trial. JAMA. 2002;288:3115–23.

    Article  PubMed  Google Scholar 

  35. Sweeney MO, Hellkamp AS, Ellenbogen KA, MOde Selection Trial Investigators, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932–7.

    Article  PubMed  Google Scholar 

  36. Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: the RD-CHF study. Pacing Clin Electrophysiol. 2007;30(Suppl 1):S23–30.

    PubMed  Google Scholar 

  37. • Curtis AB, Worley SJ, Adamson PB, Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585–93. This trial is instructive in planning pacing strategy in patients with high pacing requirements.

    Article  CAS  PubMed  Google Scholar 

  38. Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2011;8:1088–94.

    Article  PubMed  Google Scholar 

  39. Upadhyay GA, Choudhry NK, Auricchio A, Ruskin J, Singh JP. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52:1239–46.

    Article  PubMed  Google Scholar 

  40. Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (cardiac resynchronization therapy in atrial fibrillation patients multinational registry). JACC Heart Fail. 2013;1:500–7.

    Article  PubMed  Google Scholar 

  41. Penn J, Goldenberg I, Moss AJ, MADIT-CRT Trial Investigators, et al. Improved outcome with preventive cardiac resynchronization therapy in the elderly: a MADIT-CRT substudy. J Cardiovasc Electrophysiol. 2011;22:892–7.

    Article  PubMed  Google Scholar 

  42. Killu AM, Wu JH, Friedman PA, et al. Outcomes of cardiac resynchronization therapy in the elderly. Pacing Clin Electrophysiol. 2013;36:664–72.

    Article  PubMed  Google Scholar 

  43. Höke U, Putter H, Van Der Velde ET, et al. Left ventricular reverse remodeling, device-related adverse events, and long-term outcome after cardiac resynchronization therapy in the elderly. Circ Cardiovasc Qual Outcomes. 2014;7:437–44.

    Article  PubMed  Google Scholar 

  44. Olechowski B, Sands R, Zachariah D, et al. Is cardiac resynchronisation therapy feasible, safe and beneficial in the very elderly? J Geriatr Cardiol. 2015;12:497–501.

    PubMed  PubMed Central  Google Scholar 

  45. Dickstein K, Vardas PE, Auricchio A, Committee for Practice Guidelines of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG), et al. 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the heart failure association and the European heart rhythm association. Eur J Heart Fail. 2010;12:1143–53.

    Article  PubMed  Google Scholar 

  46. Yancy CW, Jessup M, Bozkurt B, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.

    Article  PubMed  Google Scholar 

  47. Thibault B, Harel F, Ducharme A, LESSER-EARTH Investigators, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex. Circulation. 2013 26;127(8):873-81. https://doi.org/10.1161/CIRCULATIONAHA.112.001239

  48. Thibault B, Harel F, Ducharme A, LESSER-EARTH Investigators, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the evaluation of resynchronization therapy for heart failure (LESSER-EARTH) trial. Circulation. 2013;127:873–81.

    Article  CAS  PubMed  Google Scholar 

  49. Ruschitzka F, Abraham WT, Singh JP, EchoCRT Study Group, et al. Cardiac- resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–405.

    Article  CAS  PubMed  Google Scholar 

  50. Versteeg H, Schiffer AA, Widdershoven JW, et al. Response to cardiac resynchronization therapy: is it time to expand the criteria? Pacing Clin Electrophysiol. 2009;32:1247–56.

    Article  PubMed  Google Scholar 

  51. Packer M. Proposal for a new clinical end point to evaluate the ef cacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7:176–82.

    Article  CAS  PubMed  Google Scholar 

  52. Pitzalis MV, Iacoviello M, Romito R, et al. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol. 2002;40:1615–22.

    Article  PubMed  Google Scholar 

  53. Bleeker GB, Bax JJ, Fung JW, et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol. 2006;97:260–3.

    Article  PubMed  Google Scholar 

  54. Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J. 2007;153:105–12.

    Article  PubMed  Google Scholar 

  55. Chalil S, Foley PW, Muyhaldeen SA, et al. Late gadolinium enhancement- cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace. 2007;9:1031–7.

    Article  PubMed  Google Scholar 

  56. Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall brosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2012;60:1659–67.

    Article  PubMed  Google Scholar 

  57. Chalil S, Stegemann B, Muhyaldeen S, et al. Intraventricular dyssynchrony predicts mortality and morbidity following cardiac resynchronization therapy: a study using cardiovascular magnetic resonance tissue synchronization imaging. J Am Coll Cardiol. 2007;50:243–52.

    Article  PubMed  Google Scholar 

  58. Arshad A, Moss AJ, Foster E, MADIT-CRT Executive Committee, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (multicenter automatic de brillator implantation trial with cardiac resynchronization therapy) trial. J Am Coll Cardiol. 2011;57:813–20.

    Article  PubMed  Google Scholar 

  59. Leyva F, Foley PW, Chalil S, Irwin N, Smith RE. Female gender is associated with a better outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2011;34:82–8.

    Article  PubMed  Google Scholar 

  60. Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608–16.

    Article  PubMed  Google Scholar 

  61. Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol. 2012;59:1509–18.

    Article  PubMed  Google Scholar 

  62. Saba S, Marek J, Schwartzman D, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the speckle tracking assisted resynchronization therapy for electrode region trial. Circ Heart Fail. 2013;6:427–34.

    Article  CAS  PubMed  Google Scholar 

  63. Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:29–38.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Pappone C, Ćalović Ž, Vicedomini G, Cuko A, et al. Improving cardiac resynchronization therapy response with multipoint left ventricular pacing: twelve-month follow-up study. Heart Rhythm. 2015;12(6):1250–8. https://doi.org/10.1016/j.hrthm.2015.02.008.

    Article  PubMed  Google Scholar 

  65. White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol. 2006;48:1953–60.

    Article  PubMed  Google Scholar 

  66. Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography- guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010;122:2660–8.

    Article  PubMed  Google Scholar 

  67. Abraham WT, Gras D, Yu CM, Guzzo L, Gupta MS, FREEDOM Steering Committee. Rationale and design of a randomized clinical trial to assess the safety and ef cacy of frequent optimization of cardiac resynchronization therapy: the frequent optimization study using the QuickOpt method (FREEDOM) trial. Am Heart J. 2010;159:944–948.e1.

    Article  PubMed  Google Scholar 

  68. Martin DO, Lemke B, Birnie D, Adaptive CRT Study Investigators, et al. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm. 2012;9:1807–14.

    Article  PubMed  Google Scholar 

  69. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002;13:399–405.

    Article  PubMed  Google Scholar 

  70. Carson PE, Johnson GR, Dunkman WB, for the V-HeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT studies. Circulation. 1993;87:VI-102–10.

    CAS  Google Scholar 

  71. Deedwania PC, Singh BN, Ellenbogen KA, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observation from the veterans affairs congestive heart failure trial on antiarrhythmic therapy (CHF-STAT). Circulation. 1998;98:2574–9.

    Article  CAS  PubMed  Google Scholar 

  72. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation. 1991;84:40–8.

    Article  CAS  PubMed  Google Scholar 

  73. The CONSENSUS. Trial study group: effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian Enalapril survival study (CONSENSUS). N Engl J Med. 1987;316:1429–35.

    Article  Google Scholar 

  74. Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med. 2007;357:1000–8.

    Article  CAS  PubMed  Google Scholar 

  75. Brenyo A, Link MS, Barsheshet A, et al. Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT. J Am Coll Cardiol. 2011;58:1682–9.

    Article  PubMed  Google Scholar 

  76. Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol. 2006;48:734–43.

    Article  PubMed  Google Scholar 

  77. Sharma PS, Dandamudi G, Naperkowski A, Oren JW, Storm RH, Ellenbogen KA, et al. Permanent his-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice. Heart Rhythm. 2015;12(2):305–12.

    Article  PubMed  Google Scholar 

  78. Dresing TJ, Natale A. Congestive heart failure treatment: the pacing approach. Heart Fail Rev. 2001;6(1):15–25.

    Article  CAS  PubMed  Google Scholar 

  79. Tanno K, Miyoshi F, Watanabe N, MADIT II. The Multicenter Automtic De brillator Implantation Trial, et al. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J. 2005;69:19–22.

    Article  PubMed  Google Scholar 

  80. Cannom DS, Rider AK, Stinson EB, Harrison DC. Electrophysiologic studies in the denervated transplanted human heart. II. Response to norepinephrine, isoproterenol and propranolol. Am J Cardiol. 1975;36:859.

    Article  CAS  PubMed  Google Scholar 

  81. Yusuf S, Theodoropoulos S, Mathias CJ, et al. Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta-adrenergic blockade. Circulation. 1987;75:696.

    Article  CAS  PubMed  Google Scholar 

  82. Ellenbogen KA, Thames MD, DiMarco JP, et al. Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. Circulation. 1990;81:821.

    Article  CAS  PubMed  Google Scholar 

  83. Enriquez AD, Calenda B, Miller MA, Anyanwu AC, Pinney SP. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol. 2013;6(4):668–74. https://doi.org/10.1161/CIRCEP.113.000457.

    Article  CAS  PubMed  Google Scholar 

  84. Zipes DP, et al. Determining the feasibility of spinal cord Neuromodulation for the treatment of chronic systolic heart failure: the DEFEAT-HF study. JACC Heart Fail. 2016;4:129–36.

    Article  PubMed  Google Scholar 

  85. Halbach M, Fritz T, et al. Baroreflex activation therapy in heart failure with reduced ejection fraction: available data and future perspective. Curr Heart Fail Rep. 2016;13(2):71–6.

    Article  CAS  PubMed  Google Scholar 

  86. Dorian P, Philippon F, Thibault B, et al. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm. 2004;1:540–7.

    Article  PubMed  Google Scholar 

  87. Bänsch D, Steffgen F, Grönefeld G, et al. The 1+1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation. 2004;110:1022–9.

    Article  PubMed  Google Scholar 

  88. Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation. 2006;113:2871–9.

    Article  PubMed  Google Scholar 

  89. Swerdlow CD, Chen PS, Kass RM, Allard JR, Peter CT. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. JAm Coll Cardiol. 1994;23:1342–55.

    Article  CAS  Google Scholar 

  90. Rinaldi CA, Simon RD, Baszko A, et al. A 17 year experience of inappropriate shock therapy in patients with implantable cardioverterdefibrillators: are we getting any better? Heart. 2004;90:330–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. •• Epstein AE, DiMarco JP, Ellenbogen KA, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and Antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1–62. The Guidelines for device implantation are comprehensive and updated regularly.

    Article  PubMed  Google Scholar 

  92. Yu CM, Fung WH, Lin H, et al. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol. 2003;91:684–8.

    Article  PubMed  Google Scholar 

  93. Lee E, Chen R, Aziz S, et al. Socio cultural barriers to device therapy among Asian patients with heart failure. Eur J Heart Fail. 2012;11(Suppl 1):S268.

    Google Scholar 

  94. Knight CS, Tallaj JA, Rayburn BK, et al. Bradycardia and syncope as a presentation of cardiac allograft rejection involving the conducting system. Cardiovasc Pathol. 2010;19:117.

    Article  PubMed  Google Scholar 

  95. Tse HF, Turner S, Sanders P, et al. The Dual Targeted Thoracic Spinal Cord Stimulation for HEArt Failure as a Restorative Treatment: First-In-Man Experience. Heart Rhythm 2015;12(3).

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Hahnemann University Hospital, Drexel University College of Medicine, 245 North 15th Street, Suite 6122, Philadelphia, PA, 19102, USA

    Brett G. Angel, Heath Saltzman & Luke S. Kusmirek

Authors
  1. Brett G. Angel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heath Saltzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luke S. Kusmirek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brett G. Angel.

Ethics declarations

Conflict of Interest

Brett G. Angel, Heath Saltzman, and Luke S. Kusmirek declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Angel, B.G., Saltzman, H. & Kusmirek, L.S. Device Management in Heart Failure. Curr Cardiol Rep 19, 114 (2017). https://doi.org/10.1007/s11886-017-0914-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-017-0914-2

Keywords

Search

Navigation